Therese‐Marie Stachyra

Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors

Philipp Holzer, Keiichi Masuya, Pascal Furet et al. · Journal of Medicinal Chemistry · 2015 · 202 citations · Full text

Dihydroisoquinolinone Derivative, Drug Target, Molecular Biology +18

In vitro activity of the  -lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases

Therese‐Marie Stachyra, Premavathy Levasseur, Marie-Claude Péchereau et al. · Journal of Antimicrobial Chemotherapy · 2009 · 171 citations · Full text

Mechanism of Action of the Antibiotic NXL101, a Novel Nonfluoroquinolone Inhibitor of Bacterial Type II Topoisomerases

Michael T. Black, Therese‐Marie Stachyra, Denis Platel et al. · Antimicrobial Agents and Chemotherapy · 2008 · 141 citations · Full text

Mechanistic Studies of the Inactivation of TEM-1 and P99 by NXL104, a Novel Non-β-Lactam β-Lactamase Inhibitor

Therese‐Marie Stachyra, Marie-Claude Péchereau, Jean‐Michel Bruneau et al. · Antimicrobial Agents and Chemotherapy · 2010 · 140 citations · Full text

Mechanistic Studies, Antimicrobial Chemotherapy, Chemical Biology +16

Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53–MDM2 Inhibitor HDM201

Sébastien Jeay, Stéphane Ferretti, Philipp Holzer et al. · Cancer Research · 2018 · 85 citations · Full text